Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes.

Abstract

Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

• Authors: Morten Møller Poulsen, Karen Fjeldborg, Marie Juul Ornstrup, Thomas Nordstrøm Kjær, Mark Klitgaard Nøhr, Steen Bønløkke Pedersen
• Journal: Biochimica et biophysica acta (Biochim Biophys Acta) Vol. 1852 Issue 6 Pg. 1124-36 (Jun 2015) ISSN: 0006-3002 [Print] Netherlands
• PMID: 25583116 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2015 Elsevier B.V. All rights reserved.

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Stilbenes
• Resveratrol

Topics

• Adipose Tissue (drug effects, metabolism)
• Animals
• Anti-Inflammatory Agents, Non-Steroidal (pharmacology, therapeutic use)
• Clinical Trials as Topic
• Humans
• Inflammation (drug therapy)
• Obesity (drug therapy)
• Resveratrol
• Stilbenes (pharmacology, therapeutic use)
• Translational Research, Biomedical